Drugs / Autologous MUC1-activated T-cells
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06483048 | Sep 2024 → Sep 2028 expected | fallopian tube carcinosarcoma, ovarian carcinosarcoma, primary peritoneal carcinoma | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 1 | NCT05411497 | Jun 2022 → Aug 2027 expected | plasma cell myeloma | Mayo Clinic | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous MUC1-activated T-cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05411497 ↗ |
| Action | Deplete | “may help the body's immune system identify and kill cancer cells.” NCT05411497 ↗ |
| Modality | Cell therapy | “MUC1-activated T cells are made from the body's own T cells.” NCT05411497 ↗ |
| Route | Intravenous | “MUC1-activated T-cells IV over 10 minutes to 1 hour on day 0.” NCT05411497 ↗ |
| Target | MUC1 | “The manufactured T-cells are made to target the MUC1 genetic marker” NCT05411497 ↗ |